Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.4
4.5
Journals
Microorganisms
Special Issues
Updates on HBV Infection
share announcement

Updates on HBV Infection

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Virology".

Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 41797

Special Issue Editor

Dr. Isabelle Chemin

E-Mail Website
Guest Editor
Centre de Recherche en Cancérologie de Lyon INSERM U1052, CNRS UMR5286, Université de Lyon, Lyon, France
Interests: HBV variants; hepatocellular carcinoma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Achieving the WHO diagnostic objectives by 2030 of 90% of people with chronic hepatitis B and treating 90% of eligible people to prevent the development of hepatocellular cancer will require a substantial scale-up of tests and treatments. The improvement of the cascade of care will require us to address and overcome the following main current obstacles: diagnosis of populations in different countries including low/middle income groups, the need for confirmation of viral load, the validation of affordable tests, and the stratification of liver disease before treatment. Other limiting factors include a lack of knowledge of infection of the community, stigma and fear of disclosure, distance from care sites, lack or cost of transportation, and long waiting times in health establishments. Therefore, this effort will include an educational valence for awareness on hepatitis B virus (HBV) infection and liver cancer in the targeted population, providing the use of a rapid diagnostic orientation test (TROD) with provision of a rapid test result including confirmation of the viral load, an immediate DNA test following a TROD-positive result, use of non-invasive tests for stratification of liver disease, and viral detection and therefore quick start of treatment.

In this context, this Special Issue aims to decipher the barriers in terms of the prevention, the diagnosis, and access to treatment of patients with viral hepatitis; propose new biomarkers; and explore viral variability in order to help expand access to anti-viral treatments for HBV chronic carriers.

Dr. Isabelle Chemin
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (11 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review, Other

3 pages, 199 KiB  
Editorial
Special Issue: “Updates on HBV Infection”
by Isabelle Chemin and Flor Helene Pujol
Microorganisms 2022, 10(3), 580; https://0-doi-org.brum.beds.ac.uk/10.3390/microorganisms10030580 - 07 Mar 2022
Cited by 3 | Viewed by 1519
Abstract
Hepatitis B virus (HBV) infection remains a global public health issue: a number of barriers still hamper the control of the HBV epidemic and in finding a cure for HBV [...] Full article
(This article belongs to the Special Issue Updates on HBV Infection)

Research

Jump to: Editorial, Review, Other

9 pages, 413 KiB  
Communication
High Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities
by Jan-Hendrik Bockmann, Matin Kohsar, John M. Murray, Vanessa Hamed, Maura Dandri, Stefan Lüth, Ansgar W. Lohse and Julian Schulze-zur-Wiesch
Microorganisms 2021, 9(5), 968; https://0-doi-org.brum.beds.ac.uk/10.3390/microorganisms9050968 - 30 Apr 2021
Cited by 7 | Viewed by 2166
Abstract
Background: The prevalence of metabolic and cardiovascular diseases is rising worldwide. However, little is known about the impact of such disorders on hepatic disease progression in chronic hepatitis B (CHB) during the era of potent nucleo(s)tide analogues (NAs). Methods: We retrospectively analyzed a [...] Read more.
Background: The prevalence of metabolic and cardiovascular diseases is rising worldwide. However, little is known about the impact of such disorders on hepatic disease progression in chronic hepatitis B (CHB) during the era of potent nucleo(s)tide analogues (NAs). Methods: We retrospectively analyzed a single-center cohort of 602 CHB patients, comparing the frequency of liver cirrhosis at baseline and incidences of liver-related events during follow-up (hepatocellular carcinoma, liver transplantation and liver-related death) between CHB patients with a history of diabetes, obesity, hypertension or coronary heart disease (CHD). Results: Rates of cirrhosis at baseline and liver-related events during follow-up (median follow-up time: 2.51 years; NA-treated: 37%) were substantially higher in CHB patients with diabetes (11/23; 3/23), obesity (6/13; 2/13), CHD (7/11; 2/11) or hypertension (15/43; 4/43) compared to CHB patients without the indicated comorbidities (26/509; 6/509). Multivariate analysis identified diabetes as the most significant predictor for cirrhosis (p = 0.0105), while comorbidities did not correlate with liver-related events in pre-existing cirrhosis. Conclusion: The combination of metabolic diseases and CHB is associated with substantially increased rates of liver cirrhosis and secondary liver-related events compared to CHB alone, indicating that hepatitis B patients with metabolic comorbidities warrant particular attention in disease surveillance and evaluation of treatment indication. Full article
(This article belongs to the Special Issue Updates on HBV Infection)
►▼ Show Figures

Figure 1

20 pages, 4584 KiB  
Article
Conformational Plasticity of Hepatitis B Core Protein Spikes Promotes Peptide Binding Independent of the Secretion Phenotype
by Cihan Makbul, Vladimir Khayenko, Hans Michael Maric and Bettina Böttcher
Microorganisms 2021, 9(5), 956; https://0-doi-org.brum.beds.ac.uk/10.3390/microorganisms9050956 - 29 Apr 2021
Cited by 8 | Viewed by 2676
Abstract
Hepatitis B virus is a major human pathogen, which forms enveloped virus particles. During viral maturation, membrane-bound hepatitis B surface proteins package hepatitis B core protein capsids. This process is intercepted by certain peptides with an “LLGRMKG” motif that binds to the capsids [...] Read more.
Hepatitis B virus is a major human pathogen, which forms enveloped virus particles. During viral maturation, membrane-bound hepatitis B surface proteins package hepatitis B core protein capsids. This process is intercepted by certain peptides with an “LLGRMKG” motif that binds to the capsids at the tips of dimeric spikes. With microcalorimetry, electron cryo microscopy and peptide microarray-based screens, we have characterized the structural and thermodynamic properties of peptide binding to hepatitis B core protein capsids with different secretion phenotypes. The peptide “GSLLGRMKGA” binds weakly to hepatitis B core protein capsids and mutant capsids with a premature (F97L) or low-secretion phenotype (L60V and P5T). With electron cryo microscopy, we provide novel structures for L60V and P5T and demonstrate that binding occurs at the tips of the spikes at the dimer interface, splaying the helices apart independent of the secretion phenotype. Peptide array screening identifies “SLLGRM” as the core binding motif. This shortened motif binds only to one of the two spikes in the asymmetric unit of the capsid and induces a much smaller conformational change. Altogether, these comprehensive studies suggest that the tips of the spikes act as an autonomous binding platform that is unaffected by mutations that affect secretion phenotypes. Full article
(This article belongs to the Special Issue Updates on HBV Infection)
►▼ Show Figures

Figure 1

10 pages, 966 KiB  
Communication
Hepatitis B Virus Genotype Study in West Africa Reveals an Expanding Clade of Subgenotype A4
by Rayana Maryse Toyé, Damien Cohen, Flor Helene Pujol, Amina Sow-Sall, Gora Lô, Kunikazu Hoshino, Masashi Mizokami, Fabien Zoulim, Maud Lemoine, Coumba Touré-Kane and Isabelle Chemin
Microorganisms 2021, 9(3), 623; https://0-doi-org.brum.beds.ac.uk/10.3390/microorganisms9030623 - 17 Mar 2021
Cited by 6 | Viewed by 2353
Abstract
Hepatitis B virus (HBV) classification comprises up to 10 genotypes with specific geographical distribution worldwide, further subdivided into 40 subgenotypes, which have different impacts on liver disease outcome. Though extensively studied, the classification of subgenotype A sequences remains ambiguous. This study aimed to [...] Read more.
Hepatitis B virus (HBV) classification comprises up to 10 genotypes with specific geographical distribution worldwide, further subdivided into 40 subgenotypes, which have different impacts on liver disease outcome. Though extensively studied, the classification of subgenotype A sequences remains ambiguous. This study aimed to characterize HBV isolates from West African patients and propose a more advanced classification of subgenotype A. Fourteen HBV full-length genome sequences isolated from patients from The Gambia and Senegal were obtained and phylogenetically analyzed. Phylogenetic analysis of HBV genotype A sequences isolated from Senegalese and Gambian patients exhibited separate clusters from the other known and confirmed subgenotypes A (A1, A2, A6). Most of the sequences (10/14) clustered with an isolate from Cuba, reported as subgenotype A4 (supported by maximal bootstrap value). Four isolates from The Gambia and Senegal clustered separately from all other subgenotypes and samples sequenced in the study. Three of which from The Gambia, designated as an expanding clade of subgenotype A4, exhibited a mean inter-subgenotypic nucleotide divergence over the entire genome sequence higher than 4% in comparison with the other subgenotypes and the other isolates sequenced in the study, except with subgenotype A4 isolates (3.9%), and this was supported by a maximal bootstrap value. The last one from Senegal seemed to be an expanding subgenotype close to the new clade of A4. Amino acid analysis unveiled a novel motif specific to these isolates. This study revealed an expanding evolution of HBV subgenotype A and novel amino acid motifs. It also highlighted the need for a consensus regarding the analysis and classification of HBV sequences. Full article
(This article belongs to the Special Issue Updates on HBV Infection)
►▼ Show Figures

Figure 1

12 pages, 275 KiB  
Article
Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers
by Romina Salpini, Vincenzo Malagnino, Lorenzo Piermatteo, Tiziana Mulas, Mohammad Alkhatib, Rossana Scutari, Elisabetta Teti, Carlotta Cerva, Katia Yu La Rosa, Marta Brugneti, Ada Bertoli, Benedetta Rossi, Vera Holzmayer, Jeffrey Gersch, Mary Kuhns, Gavin Cloherty, Francesca Ceccherini-Silberstein, Carlo-Federico Perno, Marco Iannetta, Massimo Andreoni, Loredana Sarmati and Valentina Svicheradd Show full author list remove Hide full author list
Microorganisms 2020, 8(11), 1819; https://0-doi-org.brum.beds.ac.uk/10.3390/microorganisms8111819 - 18 Nov 2020
Cited by 8 | Viewed by 2213
Abstract
The anti-HBc-positive/HBsAg-negative status is frequent in HIV-infection and correlates with poor survival. Here, by highly-sensitive assays, we evaluate cryptic HBV replication and factors correlated with its detection in 81 anti-HBc-positive/HBsAg-negative HIV-infected patients. Patients were treated for >12 months with HBV-active modern combined antiretroviral-therapy [...] Read more.
The anti-HBc-positive/HBsAg-negative status is frequent in HIV-infection and correlates with poor survival. Here, by highly-sensitive assays, we evaluate cryptic HBV replication and factors correlated with its detection in 81 anti-HBc-positive/HBsAg-negative HIV-infected patients. Patients were treated for >12 months with HBV-active modern combined antiretroviral-therapy (cART) and had serum HBV-DNA < 20 IU/mL by commercial Real-Time PCR. Serum HBV-DNA was quantified by droplet digital PCR, serum HBV-RNA by an Abbott research assay, and anti-HBc titer (proposed to infer intrahepatic cccDNA) by Lumipulse/Fujirebio. Cryptic serum HBV-DNA was detected in 29.6% of patients (median (IQR): 4(1–15) IU/mL) and serum HBV-RNA in 3.7% of patients despite HBsAg-negativity and HBV-active cART. Notably, cryptic serum HBV-DNA correlated with an advanced CDC-stage (p = 0.01) and a lower anti-HBs titer (p = 0.05), while serum HBV-RNA correlated with lower nadir CD4+ cell-count (p = 0.01). By analyzing serological HBV-markers, the combination of anti-HBs < 50 mIU/mL (indicating lower immune response) plus anti-HBc > 15COI (reflecting higher HBV replicative activity) was predictive of cryptic serum HBV-DNA (OR: 4.7(1.1–21.7), p = 0.046, PPV = 62.5%, and NPV = 72%). In conclusion, cryptic HBV-replication (not detected by classical assays) characterizes a conspicuous set of anti-HBc-positive HIV-infected patients despite HBsAg-negativity and HBV-active combined antiretroviral therapy (cART). The integration of classical and novel markers may help identify patients with cryptic HBV-replication, thus optimizing the monitoring of anti-HBc-positive/HBsAg-negative HIV-infected patients. Full article
(This article belongs to the Special Issue Updates on HBV Infection)
13 pages, 1747 KiB  
Article
Clinical, Epidemiological, and Geospatial Characteristics of Patients Infected with Hepatitis C Virus Treated with Second-Generation Direct-Action Antivirals in a Reference Center in a Mesoregion of São Paulo State, Brazil
by Danilo Zangirolami Pena, Murilo Fernandes Anadão, Edilson Ferreira Flores, Mayara Namimatsu Okada, Alexandre Martins Portelinha Filho, Rodrigo Sala Ferro and Luiz Euribel Prestes-Carneiro
Microorganisms 2020, 8(10), 1575; https://0-doi-org.brum.beds.ac.uk/10.3390/microorganisms8101575 - 13 Oct 2020
Viewed by 1561
Abstract
Hepatitis virus infection is a major public health problem worldwide. Currently, Brazil has almost 700,000 cases. The Brazilian Unified Health System (SUS) provides therapeutic regimens for people infected with hepatitis C virus (HCV). We determined the clinical, laboratory, epidemiologic, and geospatial characteristics of [...] Read more.
Hepatitis virus infection is a major public health problem worldwide. Currently, Brazil has almost 700,000 cases. The Brazilian Unified Health System (SUS) provides therapeutic regimens for people infected with hepatitis C virus (HCV). We determined the clinical, laboratory, epidemiologic, and geospatial characteristics of patients infected with HCV treated with second-generation direct-action antivirals (DAAs) in a hospital reference center in São Paulo state, Brazil, using data from file records. A map was constructed using a geographic information system. From 2015 to 2018, 197 individuals received second-generation DAAs (mean age, 57.68 ± 1.36 years; interquartile range, 56.22–59.14 years; 58.9% male; 41.1% female). Genotypes 1a and 1b accounted for 75.7% of cases and the prevalent therapeutic regimen was sofosbuvir/simeprevir. Sustained viral response accounted for 98.9% and the METAVIR score F3/F4 for 50.8%. Increased alanine transferase was significantly correlated with an increase in α-fetoproteins (p = 0.01), and severe necro-inflammatory activity (p = 0.001). Associated comorbidities were found in 71.6%, mainly coronary artery and gastrointestinal disorders. The cumulative incidence in the region was 2.6 per 10,000 inhabitants. Our data highlight the role of reference hospitals in Brazil’s public health system in the treatment of HCV. Low incidence rates demonstrated the fragility of municipalities in the active search for patients. Full article
(This article belongs to the Special Issue Updates on HBV Infection)
►▼ Show Figures

Figure 1

12 pages, 1607 KiB  
Article
A New Method for Next-Generation Sequencing of the Full Hepatitis B Virus Genome from A Clinical Specimen: Impact for Virus Genotyping
by Flavia Hebeler-Barbosa, Ivan Rodrigo Wolf, Guilherme Targino Valente, Francisco Campello do Amaral Mello, Elisabeth Lampe, Maria Inês de Moura Campos Pardini and Rejane Maria Tommasini Grotto
Microorganisms 2020, 8(9), 1391; https://0-doi-org.brum.beds.ac.uk/10.3390/microorganisms8091391 - 11 Sep 2020
Cited by 7 | Viewed by 3372
Abstract
Hepatitis B virus (HBV) is an enveloped virus that induces chronic liver disease. HBV has been classified into eight genotypes (A–H) according to its genome sequence by using Sanger sequencing or reverse hybridization. Sanger sequencing is often restricted to analyzing the S gene [...] Read more.
Hepatitis B virus (HBV) is an enveloped virus that induces chronic liver disease. HBV has been classified into eight genotypes (A–H) according to its genome sequence by using Sanger sequencing or reverse hybridization. Sanger sequencing is often restricted to analyzing the S gene and is inaccurate for detecting minority genetic variants, whereas reverse hybridization detects only known mutations. Next-generation sequencing (NGS) is a robust tool for clinical virology with different protocols available. The objective of this study was to develop a new method for the study of viral genetic polymorphisms or more accurate genotyping using genome amplification followed by NGS. Plasma obtained from five chronically infected HBV individuals was used for viral DNA isolation. HBV full-genome PCR amplification was the enrichment method for NGS. Primers were used to amplify all HBV genotypes in three overlapping amplicons, following a tagmentation step and Illumina NGS. For phylogenetic analysis, sequences were extracted from the HBVdb database. We were able to amplify a full HBV genome; further, NGS was shown to be a robust method and allowed better genotyping, mainly in patients carrying mixed genotypes, classified according to other techniques. This new method may be significant for whole genome analyses, including other viruses. Full article
(This article belongs to the Special Issue Updates on HBV Infection)
►▼ Show Figures

Figure 1

Review

Jump to: Editorial, Research, Other

24 pages, 1151 KiB  
Review
A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B
by Hira Hanif, Muzammil M. Khan, Mukarram J. Ali, Pir A. Shah, Jinendra Satiya, Daryl T.Y. Lau and Aysha Aslam
Microorganisms 2020, 8(10), 1526; https://doi.org/10.3390/microorganisms8101526 - 04 Oct 2020
Cited by 11 | Viewed by 4709
Abstract
Hepatitis B virus (HBV) infection remains a global public problem despite the availability of an effective vaccine. In the past decades, nonalcoholic fatty liver disease (NAFLD) has surpassed HBV as the most common cause of chronic liver disease worldwide. The prevalence of concomitant [...] Read more.
Hepatitis B virus (HBV) infection remains a global public problem despite the availability of an effective vaccine. In the past decades, nonalcoholic fatty liver disease (NAFLD) has surpassed HBV as the most common cause of chronic liver disease worldwide. The prevalence of concomitant chronic hepatitis B (CHB) and NAFLD thus reaches endemic proportions in geographic regions where both conditions are common. Patients with CHB and NAFLD are at increased risk of liver disease progression to cirrhosis and hepatocellular carcinoma. Due to the complexity of the pathogenesis, accurate diagnosis of NAFLD in CHB patients can be challenging. Liver biopsy is considered the gold standard for diagnosing and determining disease severity, but it is an invasive procedure with potential complications. There is a growing body of literature on the application of novel noninvasive serum biomarkers and advanced radiological modalities to diagnose and evaluate NAFLD, but most have not been adequately validated, especially for patients with CHB. Currently, there is no approved therapy for NAFLD, although many new agents are in different phases of development. This review provides a summary of the epidemiology, clinical features, diagnosis, and management of the NAFLD and highlights the unmet needs in the areas of CHB and NAFLD coexistence. Full article
(This article belongs to the Special Issue Updates on HBV Infection)
►▼ Show Figures

Figure 1

20 pages, 1932 KiB  
Review
Impact of Hepatitis B Virus Genetic Variation, Integration, and Lymphotropism in Antiviral Treatment and Oncogenesis
by Keith C.K. Lau, Kelly W. Burak and Carla S. Coffin
Microorganisms 2020, 8(10), 1470; https://0-doi-org.brum.beds.ac.uk/10.3390/microorganisms8101470 - 24 Sep 2020
Cited by 16 | Viewed by 10197
Abstract
Chronic Hepatitis B Virus (HBV) infection poses a significant global health burden. Although, effective treatment and vaccinations against HBV are available, challenges still exist, particularly in the development of curative therapies. The dynamic nature and unique features of HBV such as viral variants, [...] Read more.
Chronic Hepatitis B Virus (HBV) infection poses a significant global health burden. Although, effective treatment and vaccinations against HBV are available, challenges still exist, particularly in the development of curative therapies. The dynamic nature and unique features of HBV such as viral variants, integration of HBV DNA into host chromosomes, and extrahepatic reservoirs are considerations towards understanding the virus biology and developing improved anti-HBV treatments. In this review, we highlight the importance of these viral characteristics in the context of treatment and oncogenesis. Viral genotype and genetic variants can serve as important predictive factors for therapeutic response and outcomes in addition to oncogenic risk. HBV integration, particularly in coding genes, is implicated in the development of hepatocellular carcinoma. Furthermore, we will discuss emerging research that has identified various HBV nucleic acids and infection markers within extrahepatic sites (lymphoid cells). Intriguingly, the presence of hepatocellular carcinoma (HCC)-associated HBV variants and viral integration within the lymphoid cells may contribute towards the development of extrahepatic malignancies. Improved understanding of these HBV characteristics will enhance the development of a cure for chronic HBV infection. Full article
(This article belongs to the Special Issue Updates on HBV Infection)
►▼ Show Figures

Figure 1

29 pages, 787 KiB  
Review
Recent Advances in Understanding, Diagnosing, and Treating Hepatitis B Virus Infection
by Magda Rybicka and Krzysztof Piotr Bielawski
Microorganisms 2020, 8(9), 1416; https://0-doi-org.brum.beds.ac.uk/10.3390/microorganisms8091416 - 15 Sep 2020
Cited by 24 | Viewed by 7820
Abstract
Chronic hepatitis B virus (HBV) infection affects 292 million people worldwide and is associated with a broad range of clinical manifestations including cirrhosis, liver failure, and hepatocellular carcinoma (HCC). Despite the availability of an effective vaccine HBV still causes nearly 900,000 deaths every [...] Read more.
Chronic hepatitis B virus (HBV) infection affects 292 million people worldwide and is associated with a broad range of clinical manifestations including cirrhosis, liver failure, and hepatocellular carcinoma (HCC). Despite the availability of an effective vaccine HBV still causes nearly 900,000 deaths every year. Current treatment options keep HBV under control, but they do not offer a cure as they cannot completely clear HBV from infected hepatocytes. The recent development of reliable cell culture systems allowed for a better understanding of the host and viral mechanisms affecting HBV replication and persistence. Recent advances into the understanding of HBV biology, new potential diagnostic markers of hepatitis B infection, as well as novel antivirals targeting different steps in the HBV replication cycle are summarized in this review article. Full article
(This article belongs to the Special Issue Updates on HBV Infection)
►▼ Show Figures

Figure 1

Other

8 pages, 2358 KiB  
Opinion
Contribution of HIV/AIDS-Related Human and Social Sciences Research to a Better Understanding of the Challenges of Hepatitis B Prevention, Diagnosis and Care
by Charlotte Bauquier and Marie Préau
Microorganisms 2021, 9(6), 1166; https://0-doi-org.brum.beds.ac.uk/10.3390/microorganisms9061166 - 28 May 2021
Cited by 1 | Viewed by 2066
Abstract
Recent scientific advances in hepatitis B virus research hint at the possibility of finding a cure in the medium term. In this context, the characterization of infected persons constitutes a major public health issue in terms of implementing adapted screening and prevention strategies. [...] Read more.
Recent scientific advances in hepatitis B virus research hint at the possibility of finding a cure in the medium term. In this context, the characterization of infected persons constitutes a major public health issue in terms of implementing adapted screening and prevention strategies. Overcoming the current challenges national health systems face in hepatitis B diagnosis is essential if the World Health Organization’s target of treating 80% of infected patients by 2030 is to be reached. These challenges reflect those previously faced in the fight against HIV/AIDS. Using the knowledge produced to date in Human and Social Sciences research in the fight against HIV/AIDS, we propose avenues of reflection to support and guide the development of research in the diagnosis of hepatitis B infection. More specifically, we present theoretical, methodological and epistemological considerations for how HSS research can be optimized in the following three HBV diagnosis-related areas: (i) access to screening; (ii) retention in care; and (iii) the integration of quality of life measurement in clinical trials. Full article
(This article belongs to the Special Issue Updates on HBV Infection)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-11
Back to TopTop